Jinling Pharmaceutical Co Ltd
SZSE:000919
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jinling Pharmaceutical Co Ltd
SZSE:000919
|
CN |
|
Intercontinental Exchange Inc
NYSE:ICE
|
US |
|
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
HK |
|
MPLX LP
NYSE:MPLX
|
US |
|
COFCO Biotechnology Co Ltd
SZSE:000930
|
CN |
|
L
|
La Comer SAB de CV
BMV:LACOMERUBC
|
MX |
|
E
|
Enghouse Systems Ltd
OTC:EGHSF
|
CA |
|
S
|
San Miguel Corp
XPHS:SMC
|
PH |
|
D
|
Deutsche Konsum REIT-AG
XETRA:DKG
|
DE |
|
Banco ABC Brasil SA
BOVESPA:ABCB4
|
BR |
|
P
|
Plan B Media PCL
SET:PLANB
|
TH |
Wall Street
Price Targets
Price Targets Summary
Jinling Pharmaceutical Co Ltd
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Jinling Pharmaceutical Co Ltd's stock price target?
Not Available
Jinling Pharmaceutical Co Ltd doesn't have any price targets made by Wall Street professionals.
What is Jinling Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
1%
For the last 13 years the compound annual growth rate for Jinling Pharmaceutical Co Ltd's revenue is 3%. The projected CAGR for the next 7 years is 1%.
What is Jinling Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
30%
For the last 13 years the compound annual growth rate for Jinling Pharmaceutical Co Ltd's operating income is -14%. The projected CAGR for the next 7 years is 30%.
What is Jinling Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
27%
For the last 13 years the compound annual growth rate for Jinling Pharmaceutical Co Ltd's net income is -10%. The projected CAGR for the next 7 years is 27%.
